TY - JOUR
T1 - Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease
T2 - a multicenter prospective observational study
AU - Matsuhashi, Nobuyuki
AU - Kudo, Mineo
AU - Yoshida, Norimasa
AU - Murakami, Kazunari
AU - Kato, Mototsugu
AU - Sanuki, Tsuyoshi
AU - Oshio, Atsushi
AU - Joh, Takashi
AU - Higuchi, Kazuhide
AU - Haruma, Ken
AU - Nakada, Koji
N1 - Funding Information:
Kazunari Murakami received research grants and lecture fees from Takeda Pharmaceutical and Eisai. Mototsugu Kato received research grants and lecture fees from AstraZeneca, Daiichi Sankyo, Takeda Pharmaceutical, and Eisai. Takashi Joh received research grants from AstraZeneca, Daiichi Sankyo, Takeda Pharmaceutical, and Eisai. Kazuhide Higuchi received research grants from Daiichi Sankyo, Takeda Pharmaceutical, and Eisai, and lecture fees from AstraZeneca, Daiichi Sankyo., and Eisai. Ken Haruma received research grants and lecture fees from AstraZeneca, Daiichi Sankyo, Takeda Pharmaceutical, and Eisai. The other authors declare that they have no conflict of interest.
Publisher Copyright:
© 2015, Springer Japan.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Proton pump inhibitor (PPI) therapy, the first-line treatment for gastroesophageal reflux disease (GERD), is not always effective. This study aimed to examine the effect of pretreatment patient characteristics on response to PPI therapy. Methods: Japanese outpatients with symptomatic GERD scheduled to receive endoscopy and PPI therapy were enrolled in this multicenter prospective observational study. The patients’ characteristics, including GERD and dyspeptic symptoms, anxiety, depression, and quality of life, were assessed using questionnaires before and 2 and 4 weeks after the start of PPI therapy. Factors affecting therapeutic response were examined by simple and multiple regression analyses using three patient-reported outcome measures as objective variables. Results: Data from 182 patients were analyzed. In multiple regression analysis using the residual symptom rate as an objective variable, lower GERD symptom score (p < 0.05), absence of erosive esophagitis (p < 0.05), higher epigastric pain/burning symptom score (p < 0.05), and higher depression subscale score (p < 0.05) accompanied poorer therapeutic response. In analyses using the patient’s impression of therapy, lower GERD symptom score (p < 0.05) and absence of erosive esophagitis (p < 0.05) accompanied poorer therapeutic response. In analyses using the relative GERD symptom intensity evaluated using a numeric rating scale, lower GERD symptom score (p < 0.05), higher epigastric pain/burning symptom score (p < 0.1), and lower body mass index (p < 0.05) accompanied poorer therapeutic response. Conclusions: Patients who complained of milder GERD symptoms before treatment were likely to have poorer response to PPI therapy. Association of absence of erosive esophagitis, severer epigastric pain/burning symptoms, lower body mass index, and severer depression with poorer therapeutic response was also suggested.
AB - Background: Proton pump inhibitor (PPI) therapy, the first-line treatment for gastroesophageal reflux disease (GERD), is not always effective. This study aimed to examine the effect of pretreatment patient characteristics on response to PPI therapy. Methods: Japanese outpatients with symptomatic GERD scheduled to receive endoscopy and PPI therapy were enrolled in this multicenter prospective observational study. The patients’ characteristics, including GERD and dyspeptic symptoms, anxiety, depression, and quality of life, were assessed using questionnaires before and 2 and 4 weeks after the start of PPI therapy. Factors affecting therapeutic response were examined by simple and multiple regression analyses using three patient-reported outcome measures as objective variables. Results: Data from 182 patients were analyzed. In multiple regression analysis using the residual symptom rate as an objective variable, lower GERD symptom score (p < 0.05), absence of erosive esophagitis (p < 0.05), higher epigastric pain/burning symptom score (p < 0.05), and higher depression subscale score (p < 0.05) accompanied poorer therapeutic response. In analyses using the patient’s impression of therapy, lower GERD symptom score (p < 0.05) and absence of erosive esophagitis (p < 0.05) accompanied poorer therapeutic response. In analyses using the relative GERD symptom intensity evaluated using a numeric rating scale, lower GERD symptom score (p < 0.05), higher epigastric pain/burning symptom score (p < 0.1), and lower body mass index (p < 0.05) accompanied poorer therapeutic response. Conclusions: Patients who complained of milder GERD symptoms before treatment were likely to have poorer response to PPI therapy. Association of absence of erosive esophagitis, severer epigastric pain/burning symptoms, lower body mass index, and severer depression with poorer therapeutic response was also suggested.
KW - Anxiety
KW - Depression
KW - Dyspeptic symptoms
KW - Gastroesophageal reflux disease
KW - Therapeutic response to proton pump inhibitor therapy
UR - http://www.scopus.com/inward/record.url?scp=84949532753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949532753&partnerID=8YFLogxK
U2 - 10.1007/s00535-015-1073-0
DO - 10.1007/s00535-015-1073-0
M3 - Article
C2 - 25851931
AN - SCOPUS:84949532753
VL - 50
SP - 1173
EP - 1183
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
SN - 0944-1174
IS - 12
ER -